Pancreatic ductal adenocarcinoma (PDAC) is a severe pancreatic malignancy and is
predicted to victimize 1.5% of men and women during their lifetime (Cancer statistics: SEER …

Due to extremely poor prognosis, pancreatic cancer (PDAC) represents the fourth leading
cause of cancer-related death in Western countries. For more than a decade, gemcitabine …

Pancreatic cancer (PC) remains one of the worst cancers, with almost uniform lethality. PC
risk is associated with westernized diet, tobacco, alcohol, obesity, chronic pancreatitis, and …

Pancreatic Cancer (PC) is recognized as a highly thrombogenic tumor; thus, low-molecular-
weight heparin (LMWH) such as tinzaparin is routinely used for PC patients. On the basis of …

Purpose Over the last couple of years, we have witnessed the availability of a wide variety of
different therapeutic agents and the identification of effective combinations of existing ones …

Introduction: Inhibition of the EGFR has emerged as a promising anticancer strategy, offering
improved efficacy and quality of life for patients affected by tumors. The overall level of …

The tumour vasculature plays an important role in tumour growth and metastasis. Tumour
angiogenesis provides more oxygen and nutrients to growing tumour cells, is not as tightly …

Background The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has
failed in many ways to be as potent in the anti-cancer role as pre-clinical studies would have …

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by an extremely
poor overall survival (OS) compared to other solid tumours. As the incidence of the disease …

The presence of an aberrantly activated epidermal growth factor receptor (EGFR) in many
epithelial tumors, due to its overexpression, activating mutations, gene amplification and/or …